Clinical role of serum Copeptin in acute coronary syndrome

Abstract

ObjectiveTo assess the role of Copeptin in diagnosis of acute myocardial infarction in troponin-blind period.Subjects and methodsThis study was conducted on 40 patients who presented to emergency department complaining of chest pain and were highly suspicious to have acute cardiac ischemia, in addition to 10 subjects serving as a healthy control group. Blood samples were collected for determination of CK-MB, cTnI and Copeptin. These were measured twice (in patients’ group); at 3 h and then at 6–9 h from admission time.ResultsThe first sample revealed a non-significant difference between UA group and AMI group as regards CKMB and troponin, however, high significant difference was found as regards Copeptin (Z = 5.29, P < 0.001). Moreover, ROC curve analysis of serum Copeptin for discriminating AMI group from UA group in the first sample showed diagnostic sensitivity and specificity of 100%.In conclusionDetermination of copeptin in early diagnosis of AMI has diagnostic value being superior to a conventional cTn-I within the first three hours after acute chest pain.

Copeptin Reflect Left Ventricular Systolic Function at Early Stage of Acute Myocardial Infarction in a Pig Model

“…Early identification of patients at high risk for AMI using biomarkers can guide more individualized treatment strategies. Serum copeptin can be used as a diagnostic biomarker for AMI, 15 - 18 but previous studies used different measurement timings. 23 Therefore, this study aimed to determine the time course of serum copeptin levels and investigate the correlation between serum copeptin and LV global function in a pig AMI model.…”

“…Previous studies showed that copeptin levels can be used for the diagnosis of AMI, 15 - 18 , 23 , 27 but they all used different measurement time points and the best time point still needs to be defined. In addition, because of the variations in methods and patients among studies, no direct comparisons among studies are possible.…”

“…21 With the increased use of imaging and cardiac biomarkers, there is a prospect for combining new biomarkers with imaging modalities to guide clinical practice. 26 Previous studies showed that copeptin levels can be used for the diagnosis of AMI, [15][16][17][18]23,27 but they all used different measurement time points and the best time point still needs to be defined. In addition, because of the variations in methods and patients among studies, no direct comparisons among studies are possible.…”

“…Copeptin (or C-terminal provasopressin) is a glycosylated 39-amino-acid peptide secreted into the circulation during AMI and has emerged as a novel biomarker for AMI. 13 , 14 Clinical studies suggest that serum copeptin levels can not only be used as an alternative to excluding early AMI in patients who have had negative troponin tests, 15 - 18 but also be used as an auxiliary index to evaluate left ventricular (LV) function and morbidity and mortality of heart failure following AMI. 19 , 20 Hence, serum copeptin levels could be an important biomarker for predicting long-term outcomes in AMI patients.…”

Principal Component Analysis Using For Estimating Hypertension

“…Bu çalışmalardan amaç hastalık ile ilgili daha erken ipuçları bularak erken tanı konulması ve erken tedaviye başlanmasıdır. Hatta en ideal amaç tanı koymadan önceki aşamada bu hastalığın gelişme riskinin hesaplanması ve riski fazla olan bireylerde hastalık gelişimini önlemeye yönelik önlemlerin alınmasıdır (Abd El Baky Mahmoud, Shaaban, & Ali Ramzy, 2018;Li et al, 2018;Tang & Zhou, 2019).…”